Tirzepatide is a novel peptide medication that stimulates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors
The investigators conclude that inadequately controlled patients with T2D on metformin and insulin glargine profit from the additional therapy with tirzepatide and reach statistically significant improvements in glycemic control after 40 weeks (75)
What I tend to see, though, is some increased water retention on lithium, which can resemble weight gain, but not very much
While Zepbound alone rarely causes hypoglycemia due to its glucose-dependent mechanism, the risk increases substantially when combined with insulin or sulfonylureas
At the same time, oral vaccine can increase the patient compliance and encourage the vaccination [68]
Rybelsus has been tested in people living with type 2 diabetes, who tend to lose less weight on GLP-1 medications than people without diabetes